Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, the American Cancer Society projects approximately 1.9 million new cancer cases and 608,570 cancer deaths in the United States. Solid tumors account…
Sanofi has agreed to acquire Tidal Therapeutics in a deal worth up to $470 million, including $160 million upfront. Tidal's lipid nanoparticle-mRNA platform is…
As of late 2024, the FDA has approved seven autologous CAR-T cell therapies for hematologic malignancies: Kymriah (tisagenlecleucel), Yescarta (axicabtagene…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi acquired Cambridge-based Tidal Therapeutics for $160M upfront plus up to $310M in milestones (~$470M total), gaining Tidal's mRNA-based platform for in vivo immune cell reprogramming with applications in immuno-oncology and inflammatory diseases.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Tidal Therapeutics, Inc. (this deal) | 2021 | $470M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2021 deals · Sanofi SA deals · Oncology deals